FIELD: medicine; pharmaceutics.
SUBSTANCE: object 1 is the use of 5-aminolevulinic acid or its salt or composite ester for enhancing an antitumor effect of an immune checkpoint inhibitor, where the immune checkpoint inhibitor is an anti-PD-L1 antibody or an anti-PD-1 antibody, and where the specified 5-aminolevulinic acid or its salt or composite ester is systematically injected to a subject who needs it. Object 2 is the use of 5-aminolevylinic acid or its salt or composite ester, when producing a drug for enhancing an antitumor effect of the anti-PD-L1 antibody or the anti-PD-1 antibody.
EFFECT: enhancing an antitumor effect of immune checkpoint inhibitors, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, with 5-aminolevulinic acid.
4 cl, 4 dwg, 2 ex
| Title |
Year |
Author |
Number |
| ANTICANCER AGENT |
2016 |
- Odagami, Takenao
- Kouji, Hiroyuki
- Ozawa, Yoichi
- Hori, Yusaku
|
RU2729936C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION |
2016 |
- Mehta, Vimal D.
- Rastelli, Luca
- Sapra, Aparna Katoch
|
RU2711380C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR |
2018 |
- Campbell, James J.
- Miao, Zhenhua
- Schall, Thomas J.
- Charo, Israel
- Li, Shijie
- Janson, Christine Marie
- Singh, Rajinder
- Ebsworth, Karen
|
RU2796863C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS |
2017 |
- Sharo Izrael
- Chon Khejyun
- Shall Tomas Dzh.
- Chzhan Penli
|
RU2745195C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION |
2016 |
- Mehta, Vimal D.
- Rastelli, Luca
- Sapra, Aparna Katoch
|
RU2817047C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS |
2021 |
- So, Hong Seob
- Kwak, Tae Hwan
|
RU2830359C1 |
| ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER |
2018 |
|
RU2783759C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS |
2019 |
- Li, Shijie
- Mali, Venkat Reddy
- Singh, Rajinder
- Yang, Ju
- Zhang, Penglie
|
RU2810717C2 |
| CANCER CHEMOTHERAPY USING AZABICYCLO COMPOUND |
2018 |
|
RU2821034C2 |
| COMBINED TREATMENT OF MALIGNANT NEOPLASM USING SULPHONAMIDE COMPOUND AND IMMUNOREGULATOR |
2020 |
- Ueno, Hiroyuki
- Tsukioka Sayaka
|
RU2820817C2 |
